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Oligodendrocyte progenitor cells (OPCs) can repair
demyelinated lesions by maturing into myelin-pro-
ducing oligodendrocytes. However, the OPC poten-
tial to differentiate can be prevented by inhibitory
signals present in the pathological lesion environ-
ment. Identification of these signals is essential to
promote OPC differentiation and lesion repair. We
identified an endogenous inhibitor of remyelination,
Endothelin-1 (ET-1), which is highly expressed in
reactive astrocytes of demyelinated lesions. Using
both gain- and loss-of-function approaches, we
demonstrate that ET-1 drastically reduces the rate
of remyelination. We also discovered that ET-1 acts
mechanistically by promoting Notch activation in
OPCs during remyelination through induction of
Jagged1 expression in reactive astrocytes. Pharma-
cological inhibition of ET signaling prevented Notch
activation in demyelinated lesions and accelerated
remyelination. These findings reveal that ET-1 is
a negative regulator of OPC differentiation and
remyelination and is potentially a therapeutic target
to promote lesion repair in demyelinated tissue.
INTRODUCTION
Current multiple sclerosis (MS) therapies can be effective in
patients with relapsing and remitting MS but have little impact
in promoting remyelination in tissue, leading to permanently
demyelinated lesions with substantial axonal loss (Buck and
Hemmer, 2011; Compston and Coles, 2008). Repair of demyeli-
natedMSplaques is carried out by endogenous oligodendrocyte
(OL) progenitor cells (OPCs) in a process called remyelination
(Ffrench-Constant and Raff, 1986). However, several studies
have shown that OPCs often fail to differentiate in chronic MS
lesions (Chang et al., 2002; Wolswijk, 1998). The molecular
mechanisms that prevent OPC maturation and OL regeneration
under pathological conditions are largely unknown.588 Neuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc.OPCs migrate to demyelinated lesions, proliferate, and even-
tually differentiate into mature OLs to produce myelin (Franklin
and Ffrench-Constant, 2008). This transition from a progenitor
cell to a myelinating OL can be negatively regulated by signals
that are present in the pathological lesion environment. This is
created, in part, by a dense network of reactive astrocytes
(RAs) (Compston and Coles, 2008; McKhann, 1982). It is still
poorly understood how RAs impact OPC development and
whether signals released or expressed by astrocytes limit re-
myelination (Moore et al., 2011; Nair et al., 2008). It is interesting
that recent studies have identified the Notch activator Jagged1
as a signal expressed by RAs in MS tissue that might limit
OPC differentiation and remyelination (John et al., 2002; Stid-
worthy et al., 2004; Zhang et al., 2009). However, it is still
unknown how Jagged1 expression or Notch activation is regu-
lated in demyelinated lesions and whether these pathways are
beneficial or detrimental to the overall remyelination process.
In a previous study, we identified endothelin-1 (ET-1) as a
signaling molecule synthesized in the corpus callosum (CC)
following demyelinating injury (Gadea et al., 2008). ET-1 is a
secreted signaling peptide, which has systemic roles as a vaso-
modulator in the cardiovascular system (Rubanyi and Botelho,
1991). It is interesting that RAs produce ET-1 following various
brain injuries, and we found that this peptide promotes reactive
astrogliosis in demyelinated tissue (Gadea et al., 2008; Jiang
et al., 1993). Despite the abundance of ET-1 following injury,
and its essential role in inducing reactive astrogliosis, the role
or mechanistic action of ET-1 during remyelination has not
been defined.
Here, we use the well-established lysolecithin (LPC) model of
focal demyelination to recapitulate some aspects of the focal
lesions that are found in MS tissue. Specifically, this model
allows us to investigate the time course and cell specificity of
ET-1 signaling and how it regulates remyelination efficiency
in vivo. Using both genetic and pharmacological approaches,
we demonstrate the mechanistic action of ET-1 during remyeli-
nation. We show that astrocyte-derived ET-1 inhibits OPC
differentiation and remyelination through activation of Notch
signaling and that this effect can be reversed by a clinically
used ET receptor (ET-R) panantagonist. Our results present
a therapeutic candidate to promote repair in demyelinated
lesions where OPC differentiation is stalled or limited.
Figure 1. ET-1 Expression Is Upregulated in Astrocytes in Demyelinated LPC and MS Lesions
(A and B) In dissected tissue at 3 dpl, RT-PCR analysis revealed that only ET-1 was expressed in control (A) or LPC lesions (B).
(C) At 3 and 7 dpl, there was a strong upregulation of ET-1 in astrocytes in LPC lesions. n = 4. *p < 0.05, unpaired t test, mean ± SEM.
(D and E) Confocal images from NaCl (D) and LPC (E) lesions at 7 dpl costained with anti-GFAP and anti-ET1 antibodies. Scale bar, 25 mm.
(F) Luxol fast blue/MHCII staining of chronic active MS lesions (CA). V, ventricle, NAWM, normal white matter, GM, gray matter. Scale bar, 2.5 mm.
(G) Confocal images of the active border costained with anti-ET-1 and anti-MOG antibodies. Increased numbers of ET-1+ cells were detected in the demyelinated
tissue. Scale bar, 50 mm.
(H) Coimmunolabeling revealed strong ET-1 expression in GFAP+ astrocytes in CA lesions. White arrows indicate colocalized cells. Scale bar, 30 mm.
(I) Elevated ET-1 expression coincided with large numbers of Olig1+ (nuclear) OPCs in CA lesions. No expression of ET-1 was found in OPCs. Scale bar, 30 mm.
See also Figure S1.
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ET-1 Is Expressed by RAs in MS and Murine
Demyelinated Lesions
We have previously demonstrated that the neuropeptide ET-1
is upregulated in the CC following LPC-induced focal demyelin-
ation and that overall ET-1 levels peak at 5 days postlesion (dpl)
(Gadea et al., 2008). While we found ET-1 coexpression in glial
fibrillary acidic protein positive (GFAP+) cells in the subventric-
ular zone (SVZ) during development (Gadea et al., 2009),
expression of ET-1 in astrocytes in LPC lesions had not been
analyzed. Of the three endothelin isoforms, only ET-1 mRNA
was found in the microdissected tissue from the CC and
cingulum, in either saline- or LPC-injected tissue (Figures 1A
and 1B). Further ET-1 expression analysis revealed that ET-1
was specifically upregulated in GFAP+ astrocytes within LPC
lesions (Figures 1D and 1E). The total number of ET-1+GFAP+
cells peaked between 3 and 7 dpl, and gradually decreased un-
til 30 dpl, when only very few double-labeled cells were found
(Figure 1C). Costaining with CD31, an endothelial cell marker,
showed a small increase in the number of CD31+ET-1+ cells
at 3 and 7 dpl, but there was no difference between vehicle-
and LPC-injected hemispheres (Figures S1A, S1B, and S1F
available online). CD31+ET-1+ cells made up approximately
22% and 14% of the total number of ET-1+ cells at 3 and 7dpl, respectively. (Figure S1E). We found a slight upregulation
of ET-1 in MAC1+ microglia (Figures S1C, S1D, and S1G), but
these cells only comprised 13% and 5% of the total number
of ET-1+ cells at 3 and 7 dpl, respectively. Staining was also
comparatively weak as compared to ET-1 staining in astrocytes
(Figure S1D).
Examination of ET-1 expression in the active borders of
chronic active (CA) MS lesions (Figure 1F) revealed that ET-1
was specifically upregulated in demyelination regions of the
tissue (Figures 1F and 1G). In these areas, large numbers of
ET-1-expressing astrocytes were found (Figure 1H). Further-
more, consistent with our previous observation that a high
density of immature Olig1+ OPCs (Arnett et al., 2004) populate
the active borders of CA MS lesions (Moll et al., 2013),
we found large numbers of OPCs in close proximity to ET-1+
cells in the same active borders (Figure 1I). There was no
evidence of ET-1 expression by immature OPCs (Figure 1I),
but ET-1 expression was also found in MHCII+ T cells (data
not shown).
These results demonstrate that demyelination leads to an
abrupt increase in ET-1 expression within the lesion. This in-
crease in ET-1 was conserved between experimentally induced
lesions in mice and in human MS tissue. The majority of ET-1
expression was found in astrocytes, demonstrating that they
are the predominant source of ET-1 following injury.Neuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc. 589
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Demyelination
While the effects of ET-1 on specific cell types (including astro-
cytes) have been studied in detail (Schinelli, 2006), the effect
of ET-1 on the important endogenous repair process following
demyelination has not been examined. We have previously
shown that ET-1 directly inhibits OPC differentiation in vitro
and elicits promigratory effects during the development of
the subcortical white matter (Gadea et al., 2009). Therefore,
we sought to understand the potential role of ET-1 following
LPC-induced demyelination in vivo using both gain- and loss-
of-function approaches.
First, we infused exogenous ET-1 into remyelinating lesions
and measured the extent of mature OL regeneration, using the
mature OL markers CC1 and MAG. We and others have found
that, following LPC-induced demyelination, OPC differentiation
into mature OLs begins to occur at approximately 14 dpl (Aguirre
et al., 2007). Based on our immunohistochemical analysis
(Figure 1E) and previous western blot analysis (Gadea et al.,
2008), endogenous ET-1 levels peak during the first week of
remyelination and are very low at 14 dpl. Therefore, we extended
the natural window of ET-1 release following LPC demyelina-
tion by infusing exogenous ET-1 beginning at 14 dpl by using
miniosmotic pumps.
Miniosmotic pumps containing 100 nM ET-1 were installed at
14 dpl and left until 21 dpl (Figure 2A). In the vehicle-infused LPC
lesions at 21 dpl, a large number of CC1+Olig2+ and MAG+ cells
were found, indicating substantial levels of repair (Figures 2B,
2D, 2E, and 2G). In contrast, in the ET-1-infused LPC lesions, a
significant reduction in the number of mature OLs (CC1+Olig2+
and MAG+ cells) was found (Figures 2C, 2D, 2F, and 2G). To
further characterize and label newly generatedOLs, bromodeox-
yuridine (BrdU) was injected once per day at 6, 7, and 8 dpl,
when OPCs are proliferating within the lesion (Figure 2A). We
found that, while there was little change in the number of
Olig2+BrdU+ cells between the vehicle- and ET-1-infused lesions
(Figure 2J), there was a significant decrease in the number of
CC1+Olig2+BrdU+ cells in the ET-1-infused lesions as compared
to saline controls (Figure 2K). This showed that fewer Olig2+
OPCs had matured into CC1+ OLs and that similar numbers of
early OPCs were present following the infusion. Additionally,
these results confirmed that the mature CC1+ cells that we
observed in the vehicle-infused lesions were newly generated.
Altogether, these results indicated that when the window of
ET-1 release is extended into the OPC differentiation phase of
remyelination (14–21 dpl), OL differentiation was delayed.
Loss of ET-1 Expression in Astrocytes Is Sufficient to
Accelerate OPC Differentiation and Remyelination
RAs specifically upregulate ET-1 expression during the first
week after demyelination, when OPC expansion occurs at the
expense of differentiation. The vast majority of ET-1+ cells
following demyelination were also RAs (Figure S1E). Therefore,
we eliminated ET-1 expression in astrocytes following demyelin-
ation to specifically assess the role of astrocyte-derived ET-1 on
remyelination efficiency. An ET-1flox/flox mouse was bred with an
hGFAP-Cre-ERT2mouse to selectively eliminate ET-1 expression
in astrocytes (hGFAP-Cre-ERT2;ET-1flox/flox mouse). First, we590 Neuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc.examined the expression of ET-1 in white matter RAs from de-
myelinated hGFAP-Cre-ERT2;ET-1flox/flox mice with tamoxifen
or vehicle injections (Figures 3A–3C). At the peak of ET-1 expres-
sion (5 dpl), a 76% reduction was found in the total number of
ET-1+GFAP+ cells in the lesion (Figures 3B and 3C).
Infusion of exogenous ET-1 during remyelination limited OPC
differentiation, so we measured OPC maturation following
genetic ablation of ET-1 in astrocytes to determine the effects
on OPC development. Three experimental groups were estab-
lished: (1) ET-1 fl/fl Creneg + tamoxifen, (2) ET-1 fl/fl Cre+ +
vehicle, and (3) ET-1 fl/fl Cre+ + tamoxifen. It is interesting that
we found a significant increase in the number of CC1+Olig2+
(Figures 3D–3F and 3J) and MAG+ cells (Figures 3G–3I and 3K)
in the ET-1 fl/fl Cre+ + tamoxifen mice, as compared to ET-1 fl/fl
Creneg + tamoxifen and ET-1 fl/fl Cre+ + vehicle littermates.
We also observed an increase in the CC1+/NG2+ ratio in the
ET-1 fl/fl Cre+ + tamoxifen mice as compared to controls
(Figure 3L).
Altogether, these results demonstrate that selective deletion
of ET-1 in astrocytes significantly increased the number of
mature OLs in LPC lesions after 2 weeks and shifted the OL ratio
from an immature to mature phenotype. Conversely, extended
expression of ET-1 during remyelination led to a reduction in
the number of mature OLs generated in LPC lesions. These
findings indicate that astrocyte-derived ET-1 acts as an inhibitor
of OPC differentiation and remyelination.
ET-1 Induces Jagged1 Expression in Astrocytes
We wanted to identify the mechanisms by which ET-1 acts to
limit OPC maturation. There are two potential mechanisms of
ET-1 action: (1) direct signaling to OPCs through ET-Rs and (2)
indirect signaling to OPCs through astrocytes. We have pre-
viously shown that ET-1 can act directly on OPCs to limit their
differentiation by activation of ET-Rs on their cell surface,
particularly during migration (Gadea et al., 2009). Therefore, we
wanted to investigate the effect of ET-1 signaling through
astrocytes and the resulting effects of OPC differentiation. We
previously identified ET-1 as a potent activator of astrocytes
(Gadea et al., 2008), but expression of signals by those RAs
that inhibit OPC differentiation following ET-1 exposure was
not explored. It has been previously described that RAs in MS
lesions express high levels of Jagged1, a ligand for the Notch1
receptor (John et al., 2002). In fact, elevated Jagged1 expression
by astrocytes was found in the active borders of CA MS lesions
(John et al., 2002), the same areas where we found high ET-1
expression in astrocytes and a high density of immature OPCs
(Figure 1G). In the same study, Notch1 expression was also
found on OPCs. Independent studies have also shown that
Notch1 inhibits OPC differentiation during both development
and remyelination (Genoud et al., 2002; Zhang et al., 2009). We
tested the functional relevance of Jagged1/Notch1 signaling as
a possible mechanism underlying the effects of ET-1 on OPC
differentiation during remyelination.
First, we sought to determine whether ET-1 has a role in
regulating the expression of Jagged1. In primary cultured
astrocyte monolayers, ET-1 induced a significant increase in
Jagged1 protein expression after 48 hr (Figure 4A). These
increases in Jagged1 were blocked by preincubation with the
Figure 2. ET-1 Limits OPC Differentiation following Demyelination
(A) Following LPC demyelination, miniosmotic pumps containing ET-1 were installed at 14 dpl, when endogenous ET-1 levels are low, and left until 21 dpl.
BrdU was injected once a day, from 6 to 8 dpl, to label proliferating OPCs. Sac indicates when mice were sacrificed.
(B and C) Large numbers of CC1+Olig2+ mature OLs were found in saline-infused control mice (B) at 21 dpl but not ET-1-infused mice (C). White arrows indicate
colocalized cells. Scale bars, 50 mm.
(D) A significant decrease in the number of CC1+Olig2+ OLs was found in ET-1-infused mice. n = 6. **p < 0.01, unpaired t test, mean ± SEM.
(E and F) Compared to controls (E), reduced expression of myelin proteins MAG and MBP were also found in ET-1-infused lesions (F). White arrows indicate
MAG+ cells. Scale bars, 50 mm.
(G) A significant decrease in the number of MAG+ cells was found in ET-1-infused samples. n = 6. **p < 0.01, unpaired t test, mean ± SEM.
(H and I) More BrdU+Olig2+CC1+ cells were found in saline-infused (H) but not ET-1-infused (I) samples. Scale bars, 25 mm. White arrows indicate triple-labeled
cells.
(J and K) No change was found in the total number of BrdU+Olig2+ cells (J), but a significant decrease in the number of BrdU+Olig2+CC1+ cells was found in
ET-1-infused samples (K). n = 5. **p < 0.01, unpaired t test, mean ± SEM. N.S., not significant.
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Figure 3. Selective Elimination of ET-1 in Astrocytes Accelerates OPC Differentiation following Demyelination
(A) hGFAP-Cre-ERT2;ET-1flox/floxmice were generated to selectively reduce ET-1 expression in astrocytes. Following LPC demyelination, tamoxifen was injected
once a day, from 1 to 3 dpl to induce recombination.
(B) Confocal images of anti-ET-1- and anti-GFAP-stained astrocytes. Strong ET-1 expression was seen in astrocytes in the vehicle-injected mice but not the
tamoxifen-induced mice at 5 dpl.
(C) A significant reduction (76%) in the number of ET-1+GFAP+ astrocytes was found in the tamoxifen-induced mice at 5 dpl. n = 4. **p < 0.01, unpaired t test,
mean ± SEM.
(D–I) Confocal images of ET-1 fl/fl Creneg + tamoxifen (Tam)mice in (D) and (G), ET-1 fl/fl Cre+ + vehiclemice in (E) and (H), and ET-1 fl/fl Cre+ + tamoxifenmice in (F)
and (I) at 14 dpl coimmunolabeled with anti-CC1 and anti-Olig2 in (D) through (F) or anti-MAG and anti-MBP in (G) through (I). Scale bar, 40 mm for (D) through (F)
and 50 mm for (G) through (I). White arrows indicate CC1+Olig2+ or MAG+ cells.
(J–L) Analysis of the three groups reveals a significant increase in the number of CC1+Olig2+ OLs (J) and MAG+ OLs (K) in the ET-1 fl/fl Cre+ + tamoxifen mice, as
compared to ET-1 fl/fl Creneg + tamoxifen and ET-1 fl/fl Cre+ + vehicle mice. As shown in (L), a significant increase in the ratio of CC1+ to NG2+ cells was also found
in the ET-1 fl/fl Cre+ + tamoxifen mice, as compared to controls. n = 4. *p < 0.05, and **p < 0.01, ANOVA Bonferroni post hoc, mean ± SEM.
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Figure 4. ET-1 Promotes Jagged1 Expression in Astrocytes and Notch Signaling Is Activated in OPCs during the First Week following
Demyelination
(A) Cultured primary astrocytes were treated with ET-1 for 48 hr, and expression of Jagged1 was measured by western blot.
(B) Significant increases in Jagged1 expression were found following ET-1 exposure, as compared to control and PD142,893-treated groups. n = 3 independent
cultures, with multiple replicates per sample. *p < 0.05, ANOVA Bonferroni post hoc; mean ± SEM.
(C) Confocal images of NaCl and LPC lesions at 7 dpl labeled with anti-GFAP and anti-Jagged1.
(D) A large increase in Jagged1 expression was found in astrocytes in LPC lesions. n = 4. *p < 0.05, unpaired t test, mean ± SEM. Scale bar, 30 mm.
(E) Western blot analysis of microdissected tissue from NaCl and LPC lesions at 3, 7, 14, and 30 dpl.
(F–H) Significant increases in NICD (F), Jagged1 (G), and GFAP (H) expression were found at 7 dpl. n = 7–10. *p < 0.05, **p < 0.01, and ***p < 0.001, unpaired t test,
mean ± SEM. The TNR mouse was used to measure Notch activation in LPC lesions.
(I) Confocal image of EGFP expression in NaCl and LPC lesions at 7 dpl. Scale bar, 50 mm.
(J) Quantification of the number of EGFP+ cells following demyelination. A significant increase was found at 7 dpl in LPC samples. n = 4. ****p < 0.0001, ANOVA
Bonferroni post hoc, mean ± SEM.
(K) Colocalization analysis of LPC lesions at 7 dpl. A large number of cells were EGFP+Olig2+ and EGFP+NG2+ in LPC lesions. Error bars indicate SEM.
(L and M) Confocal images of TNR LPC lesions at 7 dpl coimmunolabeled with anti-NG2 (L) and anti-Olig2 (M).
See also Figure S2.
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results indicate that astrocytes express increased levels of
Jagged1 following ET-1 exposure and that this increase is
mediated by ET-Rs.
Notch Signaling Analysis in LPC Lesions during
Remyelination
It has been previously shown that components of Notch
signaling are present in both MS lesions and in experimentally
induced LPC lesions in mice (John et al., 2002; Stidworthy
et al., 2004). Specifically, it was shown that astrocytes express
Jagged1 and OPCs express Notch1. However, to our knowl-
edge, functional activation of Notch signaling in demyelinated
lesions has not been directly demonstrated. We utilized the
transgenic Notch reporter (TNR) mouse, in which enhanced
green fluorescent protein (EGFP) is expressed on canonical
Notch activation (Mizutani et al., 2007), to study the cell
specific activation and time course of Notch signaling following
demyelination.
As demonstrated in previous studies (John et al., 2002; Stid-
worthy et al., 2004), Jagged1 was specifically upregulated
5-fold in astrocytes in LPC lesions at 7 dpl (Figures 4C and
4D). Further analysis of Notch component expression in
microdissected white matter (WM) tissue revealed increases in
Notch intracellular cleaved domain (NICD), Jagged1, and
GFAP protein levels (Figures 4E–4H). Increases in NICD levels
(Figures 4E and 4F) coincided with elevated Jagged1 expression
at 7 dpl (Figures 4E and 4G). In the same set of experiments,
we also observed high levels of GFAP expression at 7 dpl
(Figures 4E and 4H), which indicated that the highest levels of
astrogliosis coincide with maximal Notch activation. We have
previously shown that total ET-1 expression peaks at 5 dpl
(Gadea et al., 2008), and the greatest number of ET-1-expressing
astrocytes peaks between 3 and 7 dpl (Figure 1E), which, as
predicted, immediately precedes the peak of Notch activation
at 7 dpl.
Analysis of functional Notch activation in the TNR mouse
supported our earlier results. EGFP expression was specifically
upregulated in LPC lesions (Figure 4I), with the greatest number
of EGFP+ cells found at 7 dpl (Figure 4J). Costaining of these
EGFP+ cells with Hes1, a direct downstream target of the CSL/
CBF1/RPGJ transcriptional regulators, confirmed the reliability
of the TNR mouse as an indicator of canonical Notch activation
(Figure S2A). Colocalization analysis demonstrated that approx-
imately half of the EGFP+ cells were Olig2+ (Figures 4K and 4M)
and that, as expected, the majority of these cells were NG2+
OPCs (Figures 4K and 4L). It is interesting that we also found a
significant population of EGFP+IBA1+ microglia in the core of
the lesion (Figure 4K). Little or no Notch activation was found
in astrocytes (GFAP) (Figure 4K).
Altogether, these results demonstrate that Notch signaling
is activated at high levels in demyelinated tissue and that
astrocytes are likely a major regulator of Notch activation in
these lesions. ET-1 also acts to promote Jagged1 expression
in astrocytes, indicating that it might regulate Notch activation
in vivo. Components of both the ET-1 and Notch signaling
pathways are activated during the first week following demyelin-
ation, with the peak of ET-1 expression immediately preceding594 Neuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc.increases in GFAP and Jagged1 levels, indicating a possible
functional connection.
The ET-R Antagonist PD142,893 Blocks Notch
Activation In Vivo
We showed in vitro that ET-1 strongly upregulated Jagged1
expression in astrocytes and that these increases could be
blocked using PD142,893 (Figures 4A and 4B). We also found
that activation of Notch signaling in vivo coincidedwith increases
in Jagged1 expression in astrocytes in demyelinated lesions
(Figures 4C, 4D, 4E, and 4G). Therefore, we hypothesized that,
by blocking ET-R activation using PD142,893, we could reduce
Notch activation in vivo. To test this hypothesis, PD142,893
(50 mM) was infused into the remyelinating lesions of TNR mice
using miniosmotic pumps (Figures 5A and 5B), when Notch
activation remained high in OPCs (Figure 5C, bottom panels).
As predicted, strong reductions were found in total Notch
activation following PD142,893 infusion (Figures 5C–5E and
5F). Notch activation was recovered when recombinant Jagged1
Fc (2 mg/ml) was added to a mixture containing PD142,893
(Figure 5F). No overall changes in the total number of OL lineage
cells caused by infusion of the antagonist were observed be-
tween groups (Figure 5G). To further confirm that ET-1 induces
Jagged1 expression, leading to Notch activation, Jagged1
protein expression was examined in the hGFAP-Cre-ERT2;
ET-1flox/flox mouse. Jagged1 levels were significantly reduced
at 7 dpl in microdissected tissue from the ET-1 fl/fl Cre+ + tamox-
ifen mice, as compared to ET-1 fl/fl Creneg + tamoxifen and
ET-1 fl/fl Cre+ + vehicle littermates (Figures 5H and 5I).
These results demonstrate the functional connection of ET-1
and Notch signaling in vivo. PD142,893 strongly blocked Notch
activation in LPC lesions, and exogenous Jagged1 rescues
Notch activation, even when ET-1 signaling is blocked. We
also confirm in our hGFAP-Cre-ERT2;ET-1flox/flox that a reduction
in ET-1 produced by astrocytes is sufficient to reduce overall
Jagged1 levels in the lesion. These findings also confirm
that ET-1 signaling is upstream of Notch activation during
remyelination.
ET-1-Treated Astrocytes Inhibit OPC Differentiation
through Notch Signaling
ET-1 signaling inhibits remyelination and limits OPC differen-
tiation. We propose that one mechanism regulating this effect
is expression of Jagged1 by astrocytes and resulting Notch
activation in OPCs. To specifically assess the functional interac-
tion between astrocytes and OPCs, we used a coculture system.
We have shown that ET-1 promotes Jagged1 expression in
astrocytes and that ET-1 signaling promotes Notch activation
in vivo. To assess Notch activation in cocultures, OPCs from
the TNR mouse were plated on ET-1 pretreated astrocytes.
There was a significant increase in the number of EGFP+NG2+
cells in ET-1-pretreated cocultures, as compared to control
cultures, indicating enhanced Notch signaling in OPCs (Figures
6A–6D). This signaling activation was blocked by preincubation
with PD142,893 (Figures 6A–6D). To ensure that Notch activa-
tion was mediated by astrocyte-OPC contact and not soluble
factors, cocultures were performed in which TNR mouse OPCs
were plated on glass coverslips rather than in direct contact
Figure 5. Inhibition of ET Signaling Blocks Notch Activation in LPC Lesions
(A and B) Miniosmotic pumps (A) were used to infuse drugs into LPC lesions from 6 to 8 dpl (B) to coincide with the peak of Notch activation. Sac indicates when
mice were sacrificed.
(C–E) Low-magnification confocal images of EGFP expression in the core of LPC lesions at 8 dpl in saline-infused mice (C), PD142,893-infused mice (D), and
PD142,893+Jagged1Fc-infused mice (E). Scale bar, 200 mm. NG2+EGFP+ cells (shown below DAPI) show EGFP activation in OPCs within the lesions.
(F) Quantification of the number of EGFP+ cells for each condition. A significant reduction was found in the PD142,893-infused samples. Infusion of PD142,893
in combination with Jagged1Fc restored Notch activation in the lesion. n = 4–5. *p < 0.05, ANOVA Bonferroni post hoc, mean ± SEM.
(G) No significant (N.S.) change was found in the total number of Olig2+ cells per condition. Error bars indicate SEM.
(H) Western blot analysis of Jagged1 expression in microdissected tissue from the hGFAP-Cre-ERT2;ET-1flox/flox mice at 7 dpl. Tam, tamoxifen.
(I) A significant reduction in Jagged1 levels was found in the ET-1 fl/fl Cre+ + tamoxifen mice, as compared to ET-1 fl/fl Creneg + tamoxifen and ET-1 fl/fl Cre+ +
vehicle mice. n = 4–7. *p < 0.05, ANOVA Bonferroni post hoc, mean ± SEM.
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tact required for Notch receptor/ligand interaction but still
allowed soluble factors to be released into the cell culture
media. Under these conditions, very few EGFP+NG2+ OPCs
were found, with no difference between the control or ET-1-
pretreated groups (Figure 6D).
Analysis of mature OL formation in these cocultures revealed
a drastic reduction in the number of mature O1+ OLs, when
plated on astrocytes pretreated with ET-1, as compared to
untreated astrocytes (Figures 6E and 6F). Furthermore, a
reduction in the O1+/NG2+ (mature/immature) cell ratio was
seen in ET-1-pretreated cocultures, indicating a delay in OL
lineage progression (Figure 6I). This effect was blocked by
PD142,893 preincubation (Figures 6G and 6I). To ensure that
OPC development was not directly influenced by ET-1 remain-
ing in the culture media following astrocyte pretreatment, an
anti-ET-1 antibody was added to the culture media during
OPC differentiation. We have previously shown that this anti-
ET-1 antibody can functionally block ET-1 signaling in slicecultures (Gadea et al., 2009). As expected, there was no differ-
ence between the ET-1-pretreated and the ET-1-pretreated/
anti-ET-1 groups, indicating that there was little or no ET-1 re-
maining in the culture media (Figures 6H and 6I). There was
also no difference in the O1+/NG2+ cell ratio in OPCs plated
on glass coverslips (Figures S3A–S3D). This is consistent with
our TNR results, showing little or no Notch activation in these
barrier cocultures (Figure 6D).
Our findings show that Notch signaling is activated during
OPC differentiation in cocultures with astrocytes, and Notch
activation can be increased by preexposing astrocytes to ET-
1. These effects require cell-cell contact between astrocytes
and OPCs and are not mediated by soluble factors released
by astrocytes following ET-1 exposure. Finally, when OPCs
are plated on astrocytes that were preexposed to ET-1, they
exhibit a more immature phenotype and are less likely to
differentiate into mature OLs. These results establish that
astrocytes limit OPC differentiation, particularly when primed
using ET-1.Neuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc. 595
Figure 6. ET-1 Pretreated Astrocytes
Limit OPC Differentiation through Notch
Activation
OPCs from the TNR mouse were used to assess
Notch activation in astrocyte-OPC cocultures.
(A–C) Fluorescent images of control (A), ET-1-
pretreated (B), and PD142,ET-1-pretreated (C)
cocultures costained with anti-EGFP and anti-
NG2 antibodies.
(D) A significant increase in the number of
NG2+EGFP+ OPCs was found in the ET-1-pre-
treated cocultures after 48 hr, as compared to
control and PD142,893-pre-treated cocultures.
Little or no Notch activation was found in control
(control CM) or ET-1-pretreated (ET-1 CM)
barrier cocultures. n = 3–5 independent cultures
with multiple replicates per sample. *p < 0.05,
and **p < 0.01, ANOVA Bonferroni post hoc,
mean ± SEM. In wild-type cocultures, OPC dif-
ferentiation was analyzed by measuring the ratio
of O1+ to NG2+ cells.
(E–H) Fluorescent images of control (E), ET-1
(F), PD142,ET-1 (G), and ET-1, anti-ET-1 (H)
cocultures immunolabeled with anti-O1 antibody.
(I) Quantification of the O1+ to NG2+ ratio for each
coculture condition. Significant decreases in the
ratio were found in ET-1-pretreated and ET-1,
anti-ET-1-treated groups after 48 hr. n = 4
independent cultures with multiple replicates
per sample. *p < 0.05, and **p < 0.01, ANOVA
Bonferroni post hoc, mean ± SEM.
Scale bar, 50 mm for all images.
See also Figure S3.
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OPC Differentiation and Myelination In Vivo
Using a genetic loss-of-function approach, we demonstrated
that OPC differentiation is accelerated following reduction of
ET-1 levels in the lesion (Figure 3). Our data indicate that this is
due, in part, to reduced Notch activation. In fact, selective elim-
ination of Notch1 receptors on OPCs accelerated remyelination
in vivo (Zhang et al., 2009). We also found that PD142,893 was a
potent inhibitor of Notch activation in vivo (Figure 5); therefore,
we tested whether PD142,893 was a therapeutic candidate
to promote remyelination by enhancing OPC differentiation in
demyelinated lesions.
PD142,893 was directly infused into demyelinated lesions us-
ing miniosmotic pumps beginning at 6 dpl (Figure 7A). Relatively
few mature OLs were found in the saline-infused samples
(Figures 7B, 7E, 7H, and 7I), but a robust increase in CC1+ and
MAG+ was seen following PD142,893 infusion (Figures 7C, 7F,
7H, and 7I) at 14 dpl. This effect was blocked when Jagged1
Fc was infused with PD142,893 (Figures 7D, 7G, 7H, and 7I).
Increases in mature OL number were accompanied with a shift
in the O1+/NG2+ cell ratio (Figure 7J). BrdU was used to further
characterize proliferating OPCs in the lesion for each condition
(Figure S4A). At 14 dpl, we observed a significant increase in
the number of CC1+Olig2+BrdU+ cells in the PD142,893-infused
lesions, as compared to saline-infused control (SIC) and
PD142,893 + Jag1Fc-infused mice (Figures S4B–S4E). This
indicated that a greater number of OPCs had differentiated596 Neuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc.into mature OLs. It also showed that the CC1+ cells we observed
at 14 dpl in the PD142,893-infused lesions were newly generated
following demyelination.
Since ET-1 can act directly on OPCs to promote their migra-
tion and inhibit their differentiation (Gadea et al., 2009), it is un-
likely that the effects we observed on OPC differentiation were
entirely Notch mediated. To isolate the effects of Notch signaling
alone, the g-secretase inhibitor DAPT (50 mM) was infused
into demyelinated lesions. g-secretase is responsible for NICD
cleavage, which happens on binding of the Notch receptor by
Jagged1. While there was a significant increase in mature OLs
and in the CC1+/NG2+ ratio following DAPT infusion, the average
increase was lower than in PD142,893-infused samples (Figures
7H and 7I). This indicated that the positive effects of PD142,893
on oligodendrogenesis after demyelination are not entirely
Notch mediated and are likely due to direct block of ET-1
signaling to OPCs, which would lead to enhanced differentia-
tion (Gadea et al., 2009).
Markers of OL lineage progression indicate maturation but
do not necessarily imply increased production of myelin pro-
teins and formation of compact myelin. Therefore, analysis
of myelin production was examined in microdissected tissue
and at the ultrastructural level. As expected, myelin protein
analysis revealed a sharp decrease in MBP, MAG, and
CNPase levels in LPC-injected tissue infused with saline
(Figure 8A, +Saline), compared to nondemyelinated controls
(Figure 8A, left panels). Conversely, there was a strong
Figure 7. PD142,893 Accelerates OPC Differentiation
(A) Miniosmotic pumps were used to infuse drugs into LPC lesions from 6 to 14 dpl.
(B–G) Confocal images of anti-Olig2- and anti-CC1-stained or anti-MAG- and anti-MBP-stained samples from saline-infused mice in (B) and (E), PD142,893-
infused mice in (C) and (F), and PD142,893+Jagged1Fc-infused mice in (D) and (G) at 14 dpl. White arrows indicate CC1+Olig2+ or MAG+ cells. Scale bar, 50 mm.
(H–J) In (H), quantification of the number of CC1+Olig2+ cells in four groups is shown. A significant increase was seen in PD142,893- and DAPT-infused samples.
In (I), a significant increase was also seen in the number of MAG+ cells in PD142,893- and DAPT-infused samples. In (J), an increase in the CC1-to-NG2 ratio was
also found in PD142,893-infused samples. n = 7. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, ANOVA Bonferroni post hoc, mean ± SEM.
See also Figure S4.
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(Figures 8A–8D). These increases were sustained until 21 dpl,
at which point myelin levels in the SIC samples had also
recovered (Figures S5B–S5E).
Examination of the myelin sheaths at the ultrastructural
level also showed the benefits conferred by PD142,893 infusion.Electron microscopy (EM) analysis revealed large increases
in myelin thickness in the PD142,893-infused samples as
compared to SIC samples (Figures 8E and 8F). Due to increases
in myelin thickness, we observed a significant decrease in the
average G-ratio of the PD142,893 samples as compared to
SIC samples (Figure 8G). We also observed no compaction orNeuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc. 597
Figure 8. PD142,893 Accelerates Remyelination
(A–D) Miniosmotic pumps were used to infuse drugs into LPC lesions from 6 to 14 dpl. (A) shows a western blot analysis of myelin protein expression in
microdissected tissue from control, nondemyelinated tissue (left two lanes), and from LPC-injected lesions at 14 dpl infused with saline (third lane) or PD142,893
(fourth lane). Significant increases in MBP (B), MAG (C), and CNPase (D) were observed. n = 4–6. *p < 0.05, unpaired t test, mean ± SEM.
(E and F) Electron micrograph of axonal cross-sections in saline-infused (E) and PD142,893-infused (F) samples at 14 dpl. Red scale bar, 1 mm.
(G) G-ratios were calculated from electron micrographs of saline- and PD142,893-infused samples. A significant decrease in the G-ratio was found in the
PD142,893-infused samples, indicating thicker myelin sheaths. n = 3; unpaired t test, p = 0.002.
(H) Model of the effects of ET-1 on astrocytes and remyelination. (1) ET-1 is released at high levels by astrocytes following demyelination. ET-1 then acts through
an astrocyte-mediated indirect pathway or, to a lesser extent, through direct activation of ET-Rs on OPCs (Gadea et al., 2009). (2) High levels of ET-1 in the lesion
promote a reactive phenotype in astrocytes, (3) including an upregulation of Jagged1. (4) Jagged1 on RAs binds to Notch1 receptors on OPCs, which have
migrated to the demyelinated lesion to initiate the remyelination process. Activation of Notch1 receptors on OPCs by RAs inhibits OPC differentiation, leading to
delayed remyelination and fewer mature, myelinating OLs.
See also Figure S5.
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PD142,893-infused mice (Figures 8E and 8F).
Altogether, these results indicate that infusion of PD142,893
promotes early differentiation of OPCs into mature, myelinating
OLs. Early differentiation also led to thicker myelin sheaths in
the PD142,893-infused samples. PD142,893 was a more potent
promoter of OPC differentiation than DAPT infusion alone, which
indicates that multiple mechanisms contribute to the observed
beneficial effect. PD142,893 offers a promising therapeutic
avenue for lesion repair, as it strongly limits Notch activation
and promotes remyelination in LPC lesions.
DISCUSSION
Here, we demonstrate that ET-1—which is a soluble factor
released by astrocytes following demyelination—inhibits the
rate of OPC differentiation and remyelination through induction
of Jagged1 in astrocytes and activation of Notch signaling in
OPCs (see model in Figure 8H). We found that ET-1 regulates
the rate of OPC differentiation both in vitro and in vivo and that
ET-R antagonists promote remyelination, at least in part, by
preventing Notch activation. These findings to demonstrate
the importance of ET-1 signaling in myelin pathology and as a
potential therapeutic target to promote remyelination and
prevent OPC differentiation failure in MS lesions.
Although astrocytes are not the only cells that produce and
express ET-1, we found that the largest increases in ET-1
expression following demyelination were in astrocytes. Both
nonselective infusion of ET-R antagonists and selective elimina-
tion of ET-1 expression in astrocytes resulted in the acceleration
of OPC differentiation. This suggests that astrocytes are the
primary source of elevated ET-1 in the subcortical WM following
demyelination. In further support of this notion, our hGFAP-Cre-
ERT2;ET-1flox/flox data showed that the contribution of ET-1 from
microglia or endothelial cells is dispensible to the observed
remyelination phenotype. Although other ET-isoforms exist, we
found no evidence of ET-2 or ET-3 expression in the normal or
demyelinated subcortical WM. Previous studies have shown
that ET-1 is the predominant endothelin isoform in the brain
(Schinelli, 2006); and here, we demonstrate that genetic ablation
of ET-1 produced major effects on Jagged1/Notch1 signaling
and OPC differentiation. It is interesting that a recent study
demonstrated a divergent role for ET-2 as a promoter of remye-
lination in the rat cerebellum (Yuen et al., 2013). This opposing
role of ET-2 could be accounted for by differential ET-R distribu-
tion in these brain regions. Since periventricular lesions are seen
in the subcortical WM of over 80% of MS cases (Adams et al.,
1987; Ge, 2006), our data demonstrating a beneficial effect of
blocking ET-1 in this region is particularly relevant. Of note,
studies of ET-1 following other CNS injuries have been well
documented. Increases in ET-1 levels have been detected in
Alzheimer’s (Minami et al., 1995) and in astrocytes following
hypoxia/ischemia in mice (Tsang et al., 2001). ET-1 is, itself,
also an activator of astrocytes (Gadea et al., 2008; Rogers
et al., 2003). ET-R antagonists have been used to block in-
creases in the number of RAs following cortical stab wound
and optic nerve crush experiments (Koyama et al., 1999; Rogers
et al., 2003). This is consistent with our finding that infusion ofthe ET-R panantagonist Bosentan following demyelination
reduces the number of RAs in the CC (Gadea et al., 2008).
Therefore, our results could shed further light on to the role
of astrocytes in mediating recovery and repair in other CNS dis-
orders where ET-1 release is elevated.
There has been a long-standing debate about whether exten-
sive astrogliosis following injury is detrimental or beneficial to
remyelination (Brosnan and Raine, 2013; Nair et al., 2008;
Williams et al., 2007). Early evidence showed that astrocytic
scars formed in chronic MS tissue are impediments to OPC
survival, differentiation, migration, and axonal connectivity
(Fawcett and Asher, 1999; Nair et al., 2008; Silver and Miller,
2004; Su et al., 2011; Wang et al., 2011; Zhang et al., 2010).
More recent evidence has demonstrated that astrocytes can
create a permissive environment for OPC expansion and differ-
entiation within the lesion (Moore et al., 2011; Nair et al., 2008;
Schulz et al., 2012). In this study, we show that RAs express
two major inhibitory signals, first ET-1 and then Jagged1, which
ultimately lead to the inhibition of OPC differentiation. Recent
studies have demonstrated that reactive astrogliosis is not an
all-or-none cellular transformation and that specific inflamma-
tory cues or injuries can induce distinct transcriptional responses
in astrocytes both in vivo and in vitro (Hamby et al., 2012; Zama-
nian et al., 2012). Of note, it has been shown that transforming
growth factor b1 also causes an increase in Jagged1 expression
in astrocytes, suggesting that increases in Notch ligand expres-
sion might be triggered by a host of inflammatory cues (Zhang
et al., 2010). However, we demonstrate that ablation of ET-1 in
astrocytes during remyelination is sufficient to reduce the overall
levels of Jagged1 in the lesion, despite the presence of other
inflammatory signals. This strongly suggests that ET-1 is a
major signal that regulates Jagged1 expression in RAs under
pathological conditions. By modulating astrocytic ET-1, our
results also demonstrate that RAs prevent OPC differentiation
during remyelination and may, therefore, promote a nonpermis-
sive environment for recovery.
Here, we show that astrocytic expression of Jagged1 plays
a key role in Notch regulation in demyelinated lesions. Notch
signaling plays an essential role in neural development, and
its role in the adult brain has gained increased importance in
recent years (Ables et al., 2011). Both Jagged1 and Notch1
have been found in human and in murine demyelinated lesions
in the adult brain (John et al., 2002; Seifert et al., 2007; Stidwor-
thy et al., 2004), but there are conflicting reports on whether
Notch inhibits OPC differentiation during remyelination (Stidwor-
thy et al., 2004; Zhang et al., 2009). Our analysis reveals that
the Notch activator Jagged1 inhibits OPC differentiation and
that the Notch inhibitor DAPT accelerates OPC differentiation
in vivo. Therefore, our results support the notion that Notch
acts as an inhibitor of remyelination and demonstrate that Notch
signaling is regulated by ET-1 through astrocytes. Due to its
importance in awide variety of adult brain functions, understand-
ing how Notch is regulated and identifying endogenous regu-
lators of Notch activation are crucial. Our evidence that ET-1
plays such an essential role as an activator of Notch following
demyelination could improve our understanding of the mecha-
nisms underlying cell differentiation and repair in other types of
brain injury involving reactive astrogliosis and ET-1 release.Neuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc. 599
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tion and remyelination in LPC lesions occur spontaneously
around 2–3 weeks postlesion, depending on the age of the ani-
mal and location of the lesion (Aguirre et al., 2007; Arnett et al.,
2004; Fancy et al., 2011). Our results suggest that ET-1 release
during early remyelination induces Jagged1 expression in RAs,
which likely sustains expansion of the OPC population in the
lesion prior to differentiation. We hypothesize that extended or
aberrant expression of ET-1 in human MS lesions could account
for stalled OPC differentiation in this disease (Chang et al., 2002;
Wolswijk, 1998). When we tested this hypothesis in LPC lesions,
we found that extended ET-1 expression was sufficient to delay
remyelination. Other studies have shown that there could be a
critical time window for OPC differentiation (Franklin, 2002),
and our present results demonstrate that a prolonged increase
in ET-1 levels is a major contributor of the OPC differentiation
failure under pathological conditions.
Despite strong evidence that ET-1 indirectly inhibits OPC
differentiation through an astrocyte-dependent pathway, we
cannot exclude direct signaling to OPCs, which also express
ET receptors (Gadea et al., 2009; Yuen et al., 2013). In fact,
our lab has shown that ET-1 stimulates OPC migration from
the SVZ in situ and stalls OPCs in a premyelinating state
without any effect on OPC proliferation (Gadea et al., 2009).
This direct function of ET-1 inhibits OPC differentiation during
migration and possibly within the lesion as well (see model in
Figure 8H). These findings, together with the present report,
indicate that ET-1 could act via both direct and indirect path-
ways to limit OPC differentiation. However, it is worth noting
that direct exposure of OPCs to ET-1 has produced mixed
results, and ET-1 or ET-R agonists have been found in other
studies to promote OPC differentiation in vitro (Jung et al.,
2011; Yuen et al., 2013). This conflicting evidence suggests
that the direct effect of ET-1 on OPCs in vitro might not
reflect their response in vivo. Our present studies further
support the notion that direct ET-1 signaling to OPCs may
not play a significant role in regulating differentiation within
the lesion itself. The infusion of DAPT, to isolate Notch effects,
strongly promoted OPC differentiation at a rate almost equiva-
lent to PD142,896 infusion, suggesting that astrocyte-derived
ET-1 and the Jagged1-mediated indirect pathway contributes
much more significantly to limiting the rate of remyelination
within the lesion.
To our knowledge, this is the first study that successfully
identifies an ET-R antagonist as a promyelinating compound
in vivo. PD142,893, a very potent inhibitor of ET-1 signaling,
prevented Jagged1 induction and Notch activation. For ET-1
MS therapy, one of the major challenges will be finding a
white-matter- and astrocyte-specific delivery method to mini-
mize systemic side effects (Schnyder and Huwyler, 2005; Shi
et al., 2001).The ET-R panantagonist Bosentan (Tracleer) (Rubin
et al., 2002) is an approved drug currently used to treat pulmo-
nary arterial hypertension (PAH) and displays an affinity to
ET-Rs that is similar to that of PD142,893 (Maguire et al.,
2012). Some MS patients with PAH respond to Bosentan
(Ledinek et al., 2009). Therefore, PD142,893 and other ET-R
panantagonists could offer a promising therapeutic avenue to
promote lesion repair for patients with MS.600 Neuron 81, 588–602, February 5, 2014 ª2014 Elsevier Inc.EXPERIMENTAL PROCEDURES
Animals
TNR (#005854) and C57bl/6n mice were purchased from the Jackson
Laboratory and Charles River Laboratories, respectively. Floxed ET-1 mice
were obtained from Dr. Ralph Shohet at the University of Hawaii and are
described elsewhere (Shohet et al., 2004). The hGFAP-Cre-ERT2 mice were
obtained from Dr. Flora Vaccarino at Yale University and were generated as
previously described (Ganat et al., 2006). Mice used for all experiments were
8–12 weeks old unless otherwise specified. All mouse colonies were main-
tained in the animal facility of Children’s National Medical Center, and all
animal procedures complied with the guidelines of the National Institutes of
Health and with the Children’s Research Institute Institutional Animal Care
and Use Committee guidelines.
Antibodies
For immunohistochemical, immunocytochemical, and western blot pro-
cedures, please reference the Supplemental Experimental Procedures.
Antibodies used for immunohistochemistry were anti-GFP (Abcam, 1:500),
anti-Brdu (Accurate, 1:200, 30 min 2 N HCl followed by 15 min 0.1 M boric
acid brain section pretreatment), anti-NG2 (Millipore, 1:500), anti-GFAP
(Sigma, 1:500), anti-ET-1 (Abbiotec, 1:200), anti-CD31 (BD Biosciences,
1:500), anti-Jagged1 (Iowa Hybridoma Bank, 1:200), anti-iBA1 (Wako, 1:500),
anti-MAG (Santa Cruz Biotechnology, 1:200), anti-MBP (Covance [SMI-99p],
1:1,000), anti-Hes1 (Millipore, 1:1,000), anti-CD11b/MAC1 (ABD Serotec,
1:400), anti-Olig2 (Millipore, 1:500), and anti-APC (Ab-7) (CC-1) (Calbiochem,
1:500). Antibodies used for immunocytochemistry were anti-GFP (Abcam,
1:500), anti-O1 (R&D Systems, 1:500), anti-GFAP (Sigma, 1:500), and anti-
NG2 (Millipore, 1:500). Antibodies used for western blot analysis include
anti-MBP (Covance [SMI-99p], 1:5,000), anti-MAG (Santa Cruz Biotechnology
[sc-15324], 1:200), anti-CNPase (Covance, 1:500), anti-Jagged1 (Santa Cruz
Biotechnology [sc-135955], 1:200), anti-b-actin(C4) (Millipore, 1:5,000), anti-
GFAP (Sigma, 1:5,000), and anti-NICD (Iowa Hybridoma Bank C17.9C6,
1:1,000).
LPC Injection
Mice were deeply anesthetized using 100 mg/kg ketamine and 10 mg/kg
xylazine. LPC (1% Lyso, 2 ml, EMD Chemicals) was injected unilaterally into
the external capsule of 8- to 12-week-old TNR or C57bl/6n mice using a
Hamilton syringe. On the contralateral side, 2 ml of 0.9% NaCl was injected
for control purposes. Injections were made using a stereotaxic apparatus
at the following coordinates: 1.0 mm anterior to bregma, 1.5 mm lateral,
3.0 mm deep. The date of injection was denoted as 0 dpl. Mice were then
left for a period of 3, 7, 14, or 30 dpl and then perfused for immunohisto-
chemical analysis.
Miniosmotic Pump Installation
Mice were deeply anesthetized using 100 mg/kg ketamine and 10 mg/kg
xylazine, and unilateral LPC injections were performed in 8- to 12-week-old
TNR and C57bl/6n mice. Miniosmotic pumps (Durect) were assembled using
a brain infusion kit (#0008851, Durect) with a 3 mm low-profile, 30 gauge stain-
less steel cannula and approximately 1 in. of polyethylene catheter tubing.
Both the catheter tubing and miniosmotic pumps were preloaded with 0.9%
saline, ET-1 (EMDChemicals), PD142,893 (Enzo Life Sciences), DAPT (Tocris),
or a cocktail of PD142,893 and recombinant rat Jagged1 Fc (R&D Systems)
and left overnight at 37C in 0.9% saline to initiate the pumping process and
ensure steady-state operation. For 6–8, 6–14, and 14–21 dpl infusions, we pre-
loaded pumps (pump #107D) with 100 nM ET-1, 50 mM PD142,893, 50 mM
DAPT, or 50 mM PD142,893 + 2 mg/ml Jagged1 Fc; and for 15-day infusions,
we loaded pumps with 100 mM PD142,893 (pump #1002). Due to differences
in flow rates between the 7-day (#107D) and 14-day pumps (#1002), we had
to adjust the concentration of PD142,893. The approximate PD142,893 deliv-
ery rate for both pumps was 300 pmol/day. For ET-1, the delivery rate was
60 pmol/day. Mice were reanesthetized, and the pumps were installed into
a subcutaneous pocket at the base of the neck. The catheter tubing and
cannula were led to the initial injection site, and the cannula was inserted
into the same skull perforation used for LPC injection, which was still visible.
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(#0008670, Durect). Brains were then used for immunohistochemical and
western blot analysis.
Cell Cultures
Purified astrocyte cultures were prepared from 20-day-old Sprague-Dawley
rat embryos as described elsewhere (Gallo and Armstrong, 1995; Schinelli
et al., 2001). Astrocytes were left to grow until 70%–80% confluency before
addition of 100 nM ET-1 or 100 mM PD142,893. Cell culture media was
changed in both control and ET-1/antagonist-treated groups every 24 hr,
including new ET-1/antagonist for the treated groups. For cells treated with
both ET-1 and the antagonist, PD142,893 was added 2 hr prior to the addition
of ET-1. For western blot analysis, cells were rinsed twice in ice-cold PBS
and collected in RIPA lysis buffer with protease inhibitor cocktail.
Cocultures
Glass coverslips (Fisher, 25 mM HCl treated) were coated in poly-L-lysine in
6-well plates. Purified astrocytes were plated at 75,000 cells per coverslip
and left to grow until 70%–80% confluent in 10% fetal bovine serum/
Dulbecco’s modified Eagle’s medium (DMEM). Three experimental groups
of astrocytes were then established: (1) untreated; (2) ET-1 treated; and (3)
PD142,893 treated, and then ET-1 treated, as described earlier. Purified
cortical OPC cultures were prepared from embryonic day 20 rats or P5 TNR
mice as previously described (Gallo et al., 1996; Ghiani et al., 1999). OPC
cultures were maintained in DMEM-N1 biotin-containing medium (penicillin,
100 U/ml; streptomycin, 100 mg/ml; human apo-transferrin, 50 mg/ml; biotin,
10 ng/ml; Na selenium, 25 nM; insulin, 2.5 mg/ml; putrescine, 100 mM;
progesterone 20 nM) with added platelet-derived growth factor-AA and basic
fibroblast growth factor (10 ng/ml each, R&D Systems) to inhibit differentiation.
Following astrocyte treatment, OPCs were plated on the astrocytes at a
density of 75,000 cells per coverslip in the DMEM-N1 biotin-containing
medium minus growth factors to allow differentiation. For cocultures treated
with anti-ET-1 antibody (Calbiochem, 1:500), astrocyte monolayers were
pretreated with ET-1, and during the OPC differentiation phase of the culture,
anti-ET-1 was added once per day. Cocultures were then left for a period of
48 hr to differentiate. Coverslips were then used for immunocytochemical
analysis.
Statistical Analysis
Specific numbers of animals or cultures are denoted in each figure legend.
Significance was calculated using GraphPad Prism software (http://www.
graphpad.com) using unpaired t tests for comparisons between two groups.
For multigroup comparisons, a one-way ANOVA with a Bonferroni post hoc
analysis was used.
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